Ariel Johnson, PhD

Board Member

Ariel Johnson brings together a wealth of experience across investor relations, strategy, and marketing. She is the Vice President of Strategy and Investor Relations for Endotronix. Dr. Johnson has a PhD in Oral Biology from the University of Illinois at Chicago, a M.S. in Chemistry from the University of Minnesota and a B.S. and B.A. in Chemistry, Biology and Physiology from the University of Minnesota.

She is excited to work on the board to ensure our community (and all cardiology patients) get the best possible cardiology care and MHIF is working to provide access to innovative, state-of-the-art technology to enable the best possible outcomes for the patients.

Back to Board of Directors

Give the Gift of Hope

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.